



Clinical trial results:

Long-term follow-up of study participants from GlaxoSmithKline (GSK) Biologicals'-sponsored clinical trials evaluating Human Immunodeficiency Virus vaccine [F4co (p24-RT-Nef-p17)/AS01B vaccine] (732461) for therapeutic use.

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2009-018097-64
Trial protocol	DE
Global end of trial date	19 May 2014

Results information

Result version number	v2 (current)
This version publication date	13 July 2016
First version publication date	29 May 2015
Version creation reason	• Correction of full data set Data correction due to a system error in EudraCT – Results

Trial information

Trial identification

Sponsor protocol code	114083
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01092611
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	24 September 2012
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	19 May 2014
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

- To assess the health status of HIV-infected persons who have been previously enrolled in studies evaluating the F4co/AS01B vaccine
- To assess CD4 count and viral load kinetics of HIV-infected persons who have been previously enrolled in studies evaluating the F4co/AS01B vaccine
- To assess time to (re)initiation of ART of HIV-infected persons who have been previously enrolled in studies evaluating the F4co/AS01B vaccine
- To assess the incidence of specific clinical events (cardiovascular, end stage renal and hepatic events, opportunistic infections, cancers) of HIV-infected persons who have been previously enrolled in studies evaluating the F4co/AS01B vaccine
- To evaluate the safety of the F4co/AS01B vaccine and to check the safety of study participation

Protection of trial subjects:

All subjects were supervised after vaccination/product administration with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 March 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	7 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 37
Country: Number of subjects enrolled	France: 52
Country: Number of subjects enrolled	Germany: 69
Country: Number of subjects enrolled	United States: 32
Worldwide total number of subjects	190
EEA total number of subjects	158

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	190
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Pre-assignment period milestones

Number of subjects started	190
Number of subjects completed	165

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Unknown completion reason: 25
----------------------------	-------------------------------

Period 1

Period 1 title	Year 1 (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

Partially blind for the ART-Naïve population: Results for this group may be amended at a forthcoming update of this summary as this group includes subjects previously enrolled in the ongoing 2010-021356-26 study, from which there may be more subjects to be enrolled.

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	HIV 732462 Naïve Group
------------------	------------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	GSK HIV vaccine 732462
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

No additional vaccine doses were administered in this study, all vaccine doses were administered during the primaty studies.

Arm title	Placebo Naïve Group
------------------	---------------------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Physiological Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

No additional vaccine doses were administered in this study, all vaccine doses were administered during the primaty studies.

Arm title	Blinded Naïve Group
------------------	---------------------

Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	Physiological Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

No additional vaccine doses were administered in this study, all vaccine doses were administered during the primaty studies.

Investigational medicinal product name	GSK HIV vaccine 732462
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

No additional vaccine doses were administered in this study, all vaccine doses were administered during the primaty studies.

Arm title	HIV 732462 Treated Group
------------------	--------------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	GSK HIV vaccine 732462
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

No additional vaccine doses were administered in this study, all vaccine doses were administered during the primaty studies.

Arm title	Placebo Treated Group
------------------	-----------------------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Physiological Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

No additional vaccine doses were administered in this study, all vaccine doses were administered during the primaty studies.

Number of subjects in period 1^[1]	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group
Started	9	8	129
Completed	7	8	129
Not completed	2	0	0
Lost to follow-up	2	-	-

Number of subjects in period 1^[1]	HIV 732462 Treated Group	Placebo Treated Group
Started	9	10
Completed	9	10
Not completed	0	0
Lost to follow-up	-	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of 190 enrolled, 25 have an unknown status due to ongoing study 111679 and blinded results

Baseline characteristics

Reporting groups

Reporting group title	HIV 732462 Naïve Group
Reporting group description: -	
Reporting group title	Placebo Naïve Group
Reporting group description: -	
Reporting group title	Blinded Naïve Group
Reporting group description: -	
Reporting group title	HIV 732462 Treated Group
Reporting group description: -	
Reporting group title	Placebo Treated Group
Reporting group description: -	

Reporting group values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group
Number of subjects	9	8	129
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	39.6	33.9	36
standard deviation	± 8.56	± 7.32	± 8.2
Gender categorical Units: Subjects			
Female	0	1	15
Male	9	7	114

Reporting group values	HIV 732462 Treated Group	Placebo Treated Group	Total
Number of subjects	9	10	165
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years)			0 0 0 0 0

Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
arithmetic mean	44.3	43.4	
standard deviation	± 3	± 6.8	-
Gender categorical			
Units: Subjects			
Female	1	0	17
Male	8	10	148

End points

End points reporting groups

Reporting group title	HIV 732462 Naïve Group
Reporting group description: -	
Reporting group title	Placebo Naïve Group
Reporting group description: -	
Reporting group title	Blinded Naïve Group
Reporting group description: -	
Reporting group title	HIV 732462 Treated Group
Reporting group description: -	
Reporting group title	Placebo Treated Group
Reporting group description: -	

Primary: Number of subjects with anti-retroviral therapy (ART) initiation or modification

End point title	Number of subjects with anti-retroviral therapy (ART) initiation or modification ^[1]
End point description:	
End point type	Primary
End point timeframe:	
At Year 1 post Dose 1	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	HIV 732462 Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	129	9
Units: Subjects				
Positive ART initiation	2	5	9	0
Negative ART initiation	7	3	120	0
Postitive ART modification	0	0	0	1
Negative ART modification	0	0	0	8

End point values	Placebo Treated Group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Subjects				
Positive ART initiation	0			
Negative ART initiation	0			
Postitive ART modification	1			
Negative ART modification	9			

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with ART modifications by reason

End point title	Number of subjects with ART modifications by reason ^[2]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From Year 0 to Year 1

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	HIV 732462 Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	129	9
Units: Subjects				
VL Increase	0	1	2	0
Physician Decision	0	0	0	1
CD4 Decline	1	1	6	0
Unknown	0	1	0	0
Other	1	2	1	0

End point values	Placebo Treated Group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Subjects				
VL Increase	1			
Physician Decision	0			
CD4 Decline	0			
Unknown	0			
Other	0			

Statistical analyses

No statistical analyses for this end point

Primary: Cluster of Differentiation 4 (CD4) cell count

End point title	Cluster of Differentiation 4 (CD4) cell count ^[3]
End point description:	
End point type	Primary
End point timeframe:	
At Year 1	

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	HIV 732462 Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	8	120	9
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
Positive CD4	569 (475 to 647)	494 (424 to 535)	0 (0 to 0)	732 (639 to 792)
Negative CD4	702 (463 to 941)	0 (0 to 0)	609 (500 to 721)	0 (0 to 0)

End point values	Placebo Treated Group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
Positive CD4	698 (494 to 923)			
Negative CD4	0 (0 to 0)			

Statistical analyses

No statistical analyses for this end point

Primary: Human Immunodeficiency Virus (HIV) Viral Load (VL) in all HIV+ subjects

End point title	Human Immunodeficiency Virus (HIV) Viral Load (VL) in all HIV+ subjects ^{[4][5]}
End point description:	
End point type	Primary
End point timeframe:	
At Year 1	

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis did not include the Blinded Group.

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	8	120	
Units: RNA copies/mL				
median (inter-quartile range (Q1-Q3))				
Positive VL	4.39 (4.13 to 4.67)	4.77 (4.28 to 4.88)	0 (0 to 0)	
Negative VL	4.59 (3.79 to 5.38)	0 (0 to 0)	2.78 (2.7 to 2.86)	

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with Human Immunodeficiency Virus (HIV) progression

End point title	Number of subjects with Human Immunodeficiency Virus (HIV) progression ^[6]
End point description:	
End point type	Primary
End point timeframe:	
At Year 1 post Dose 1	

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	HIV 732462 Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	129	9
Units: Subjects				
Positive HIV	1	0	0	0
Negative HIV	8	8	129	9

End point values	Placebo Treated Group			
Subject group type	Reporting group			
Number of subjects analysed	10			

Units: Subjects				
Positive HIV	0			
Negative HIV	10			

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with Adverse Events (AEs)

End point title	Number of subjects with Adverse Events (AEs) ^[7]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From Year 0 to Year 1

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	HIV 732462 Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	129	9
Units: Subjects				
Any Related AEs	0	0	0	0

End point values	Placebo Treated Group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Subjects				
Any Related AEs	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with potential Immune Diseases (pIMDs)

End point title	Number of subjects with potential Immune Diseases (pIMDs) ^[8]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From Year 0 to Year 1

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	HIV 732462 Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	129	9
Units: Subjects				
Any pIMDs	0	0	0	0

End point values	Placebo Treated Group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Subjects				
Any pIMDs	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with serious adverse events (SAEs)

End point title	Number of subjects with serious adverse events (SAEs) ^[9]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From Year 0 to Year 1

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group	HIV 732462 Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	129	9
Units: Subjects				
Any SAEs	0	0	0	2
Related SAEs	0	0	0	0

End point values	Placebo Treated Group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Subjects				
Any SAEs	0			
Related SAEs	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with undetectable VL

End point title	Number of subjects with undetectable VL ^{[10][11]}
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

At Year 1

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Analysis performed only on subjects from ART-Treated Cohort who previously participated in the 112353 study and were stable on HAART with undetectable virus load.

End point values	HIV 732462 Treated Group	Placebo Treated Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects	9	10		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with antibodies against vaccine antigens

End point title	Number of subjects with antibodies against vaccine antigens ^[12]
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At Year 1

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis did not include the Blinded Group.

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	HIV 732462 Treated Group	Placebo Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	8	8	8
Units: Subjects				
Anti-Nef [N=7,8,8,8]	3	3	5	1
Anti-P17 [N=7,8,8,8]	3	5	7	3
Anti-P24 [N=7,8,8,8]	7	8	7	7
Anti-RT [N=6,7,8,8]	5	7	8	6
Anti-F4co [N=7,8,8,8]	7	8	8	7

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-Nef, Anti-P17, Anti-P24, Anti-RT, Anti-F4co antibody concentrations

End point title	Anti-Nef, Anti-P17, Anti-P24, Anti-RT, Anti-F4co antibody concentrations ^[13]
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At Year 1

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis did not include the Blinded Group.

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	HIV 732462 Treated Group	Placebo Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	8	8	8
Units: mEL.U/mL				
geometric mean (confidence interval 95%)				
Anti-Nef [N=7,8,8,8]	586.1 (190.3 to 1805)	478.7 (220.5 to 1039.1)	634.7 (303.8 to 1326.1)	290.9 (197.6 to 428.2)
Anti-P17 [N=7,8,8,8]	286.3 (75.4 to 1087.1)	405.7 (92.3 to 1782.4)	895.8 (241.4 to 3324.5)	188.9 (79.3 to 450.2)
Anti-P24 [N=7,8,8,8]	2237.7 (264.3 to 18948.3)	2258.7 (300.4 to 16981.1)	3667.4 (608.3 to 22109.4)	1287.8 (263 to 6307.4)
Anti-RT [N=6,7,8,8]	6609.3 (282.8 to 154452.7)	11217.4 (1330.1 to 94602.4)	2883.7 (844.1 to 9851.4)	620 (145.3 to 2646.3)
Anti-F4co [N=7,8,8,8]	3448.4 (546.3 to 21769.4)	2571.6 (359.5 to 18396.4)	2503.5 (589.2 to 10637.1)	408.7 (117.5 to 1421.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with response to antigens

End point title	Number of subjects with response to antigens ^[14]
-----------------	--

End point description:

Breadth was assessed only for the HIV specific CD4+ T cells and was measured by evaluating response to at least 1, 2, 3 antigens and to all 4 antigens.

End point type	Secondary
----------------	-----------

End point timeframe:

At Year 0 and Year 1

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis did not include the Blinded Group.

End point values	HIV 732462 Treated Group	Placebo Treated Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Subjects				
One antigen, Y0 [N=8,7]	5	3		
Two antigens, Y0 [N=8,7]	4	0		
Three antigens, Y0 [N=8,7]	2	0		
Four antigens, Y0 [N=8,7]	1	0		
One antigen, Y1 [N=8,6]	4	3		
Two antigens, Y1 [N=8,6]	2	0		
Three antigens, Y1 [N=8,6]	0	0		
Four antigens, Y1 [N=8,6]	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of F4-computed fussion protein and Nef, P17, P24, RT antigens – specific cluster of differentiation CD40L+ CD4+ T- cells expressing at least two Interleukins-2 (IL-2)

End point title	Frequency of F4-computed fussion protein and Nef, P17, P24, RT antigens – specific cluster of differentiation CD40L+ CD4+ T- cells expressing at least two Interleukins-2 (IL-2) ^[15]
-----------------	--

End point description:

Magnitude was defined as the frequency of F4co, P17, P24, Nef and RT-specific CD40L+ CD4+ T-cells expressing at least IL-2.

End point type	Secondary
End point timeframe:	
At Year 0 and Year 1	
Notes:	
[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: The analysis did not include the Blinded Group.	

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	HIV 732462 Treated Group	Placebo Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	8	7
Units: cells/million T-cells				
median (inter-quartile range (Q1-Q3))				
Nef, Y0 [N=4,6,8,7]	47 (28.5 to 247)	24.5 (4 to 63)	213.5 (105.5 to 415)	61 (58 to 137)
Nef, Y1 [N=3,2,8,6]	54 (4 to 56)	24.5 (20 to 29)	156 (86 to 259)	89.5 (32 to 163)
P17, Y0 [N=4,6, 8,7]	136 (60.5 to 191.5)	131.5 (38 to 236)	270 (114 to 432.5)	173 (162 to 227)
P17, Y1 [N=3,2,8,6]	54 (4 to 185)	84.5 (45 to 124)	140 (107.5 to 259.5)	183.5 (123 to 301)
P24, Y0 [N=4,6,8,7]	127.5 (82 to 211.5)	44.5 (4 to 171)	448.5 (261.5 to 911)	327 (264 to 433)
P24, Y1 [N=3,2,8,6]	234 (47 to 242)	211 (176 to 246)	309.5 (172 to 426)	351.5 (80 to 438)
RT, Y0 [N=4,6,8,7]	198.5 (120 to 413)	44 (18 to 141)	1057.5 (243.5 to 2311)	130 (112 to 184)
RT, Y1 [N=3,2,8,6]	73 (51 to 144)	102 (65 to 139)	758 (264 to 1033)	139 (75 to 178)
F4-computed, Y0 [N=4,6,8,7]	538 (346.5 to 1007.5)	233.5 (122 to 577)	2394 (821.5 to 3817.5)	794 (610 to 873)
F4-computed, Y1[N=3,2,8,6]	373 (158 to 617)	422 (380 to 464)	1432 (702 to 1873)	849 (310 to 1259)

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of F4-computed fussion protein and Nef, P17, P24, RT antigens – specific cluster of differentiation CD40L+ CD4+ T- cells expressing at least one cytokine

End point title	Frequency of F4-computed fussion protein and Nef, P17, P24, RT antigens – specific cluster of differentiation CD40L+ CD4+ T- cells expressing at least one cytokine ^[16]
End point description:	
Magnitude was defined as the frequency of F4co, P17, P24, Nef and RT-specific CD40L+ CD4+ T-cells expressing at least one cytokine.	
End point type	Secondary
End point timeframe:	
At Year 0 and Year 1	

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis did not include the Blinded Group.

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	HIV 732462 Treated Group	Placebo Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	8	7
Units: cells/million T-cells				
median (inter-quartile range (Q1-Q3))				
Nef, Y0 [N=4,6,8,7]	53.5 (35 to 271)	78 (7 to 147)	244 (110.5 to 438.5)	78 (76 to 154)
Nef, Y1 [N=3,2,8,6]	59 (7 to 90)	100 (23 to 177)	234 (108.5 to 325)	134.5 (52 to 175)
P17, Y0 [N=4,6, 8,7]	191.5 (111.5 to 251)	162 (45 to 499)	297 (128 to 478.5)	197 (180 to 277)
P17, Y1 [N=3,2,8,6]	119 (76 to 224)	105.5 (84 to 127)	176.5 (145.5 to 298.5)	234 (126 to 377)
P24, Y0 [N=4,6,8,7]	188 (169 to 278)	99 (56 to 404)	505 (312.5 to 938)	355 (297 to 463)
P24, Y1 [N=3,2,8,6]	321 (152 to 442)	284 (259 to 309)	362 (190.5 to 541.5)	355 (101 to 551)
RT, Y0 [N=4,6,8,7]	241 (136.5 to 456.5)	49.5 (21 to 226)	1075.5 (290 to 2373)	162 (115 to 187)
RT, Y1 [N=3,2,8,6]	78 (54 to 189)	206 (190 to 222)	812 (268.5 to 1155)	181.5 (92 to 237)
F4-computed, Y0 [N=4,6,8,7]	714 (513 to 1195.5)	363.5 (226 to 1479)	2494.5 (1002.5 to 4001)	847 (728 to 954)
F4-computed, Y1 [N=3,2,8,6]	646 (341 to 824)	695.5 (588 to 803)	1563.5 (799.5 to 2349.5)	1056 (336 to 1562)

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of F4-computed fussion protein and Nef, P17, P24, RT antigens – specific cluster of differentiation CD8+ T- cells expressing at least one cytokine

End point title	Frequency of F4-computed fussion protein and Nef, P17, P24, RT antigens – specific cluster of differentiation CD8+ T- cells expressing at least one cytokine ^[17]
-----------------	--

End point description:

The Cytokine Co-expression profile was defined by the frequency of F4co, P17, P24, Nef and RT specific CD4+ (or respectively CD8+) T-cells expressing CD40L and/or IL-2 and/or TNF-α and /or IFN-γ.

End point type	Secondary
----------------	-----------

End point timeframe:

At Year 0 and Year 1

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis did not include the Blinded Group.

End point values	HIV 732462 Naïve Group	Placebo Naïve Group	HIV 732462 Treated Group	Placebo Treated Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	8	7
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
Nef, Y0 [N=4,6,8,7]	2000.5 (1714 to 5268.5)	1257 (960 to 2161)	948 (446.5 to 1905)	595 (215 to 855)
Nef, Y1 [N=3,2,8,6]	3113 (2872 to 3750)	117110 (1306 to 232914)	1049 (378.5 to 2881)	1452 (781 to 2575)
P17, Y0 [N=4,6,8,7]	6574.5 (5055.5 to 8156.5)	821 (564 to 1359)	575 (200 to 1595.5)	404 (286 to 492)
P17, Y1 [N=3,2,8,6]	9610 (423 to 10636)	1724 (1142 to 2306)	952 (436.5 to 1836.5)	976 (536 to 1258)
P24, Y0 [N=4,6,8,7]	4087.5 (764.5 to 7400)	2196.5 (753 to 4326)	2205.5 (421 to 7239)	1005 (399 to 1293)
P24, Y1 [N=3,2,8,6]	2922 (695 to 9048)	6179 (5160 to 7198)	4053 (220.5 to 10789)	2144.5 (1162 to 2892)
RT, Y0 [N=4,6,8,7]	9425.5 (5288 to 10695)	2805.5 (1696 to 5286)	1134 (655.5 to 3862)	571 (274 to 1041)
RT, Y1 [N=3,2,8,6]	10876 (3810 to 14535)	4958 (1400 to 8516)	1698.5 (857 to 3674.5)	2097 (1209 to 3930)
F4-computed, Y0 [N=4,6,8,7]	22919 (16454.5 to 27887.5)	7110.5 (6741 to 11951)	7708 (2504 to 12663.5)	2741 (2020 to 5151)
F4-computed, Y1 [N=3,2,8,6]	28738 (10905 to 32647)	129971 (19326 to 240616)	9971 (2949.5 to 16775.5)	8731 (5611 to 10583)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Unsolicited AEs from Year 0 to Year 1 post-vaccination period, SAEs from Year 0 to Year 1

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

Reporting groups

Reporting group title	HIV 732462 Naïve Group
-----------------------	------------------------

Reporting group description: -

Reporting group title	Placebo Naïve Group
-----------------------	---------------------

Reporting group description: -

Reporting group title	Blinded Naïve Group
-----------------------	---------------------

Reporting group description: -

Reporting group title	HIV 732462 Treated Group
-----------------------	--------------------------

Reporting group description: -

Reporting group title	Placebo Treated Group
-----------------------	-----------------------

Reporting group description: -

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events were reported, as no vaccine was administered.

Serious adverse events	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 129 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anal cancer			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	HIV 732462 Treated Group	Placebo Treated Group	
Total subjects affected by serious adverse events			

subjects affected / exposed	2 / 9 (22.22%)	0 / 10 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anal cancer			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	HIV 732462 Naïve Group	Placebo Naïve Group	Blinded Naïve Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 129 (0.00%)

Non-serious adverse events	HIV 732462 Treated Group	Placebo Treated Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 August 2011	Amendment 1 The names of the persons now in charge of the study have been changed on the cover page. Section 11 and Appendix C, which provide country-specific information for participating centres in France, have been added. Some aspects of study design, endpoints and study conclusion have been reworded for clarity.
06 February 2012	Amendment 2 This amendment was developed in order to extend safety follow-up to the collection of information on 1) Serious adverse events considered by the investigator to be related to study vaccination (which was performed in previous GSK-sponsored trials evaluating the F4co/AS01B vaccine) or study participation and 2) Potential immune-mediated diseases. The US BB-IND number has also been added where required by GSK's protocol template.
13 January 2014	Recent data from study TH HIV-008 (Efficacy and safety of HIV vaccine 732462 in ART-naïve HIV-1 infected persons; eTrack study number: 111679) failed to demonstrate a significant reduction of HIV-1 viral load after vaccination with two or three doses of F4co/AS01B, as compared to a placebo. The observed incidence of adverse events after F4co/AS01B vaccination, their type and severity were acceptable. No clinical relevant changes in any laboratory parameters which could be imputed to the F4co/AS01B vaccine were observed. There was no clinically significant dose-dependent reactogenicity variation. A first evaluation of the long-term safety profile has been performed in study TH HIV-011 (cf interim report Y1, includes subjects from studies TH HIV-008 and TH HIV-010), where no significant safety issue was reported. In consequence, the long-term evaluation of the benefit/risk associated with study vaccination has become irrelevant and the present TH HIV-011 study, initially planned to last 7 years, will be prematurely terminated after collection of Year 1 data for all subjects enrolled in the study. Minor changes have been implemented (e.g., update of the listing of contributing authors [names and titles], changes in tenses, addition of abbreviations), and typographical errors/misspellings have been corrected.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
------	--------------	--------------

24 September 2012	Recent data from study TH HIV-008 (Efficacy and safety of HIV vaccine 732462 in ART-naïve HIV-1 infected persons; eTrack study number: 111679) failed to demonstrate a significant reduction of HIV-1 viral load after vaccination with two or three doses of F4co/AS01B, as compared to a placebo. In consequence, the long-term evaluation of the benefit/risk associated with study vaccination has become irrelevant and the present TH HIV-011 study, initially planned to last 7 years, will be prematurely terminated after collection of Year 1 data for all subjects enrolled in the study.	-
-------------------	--	---

Notes:

Limitations and caveats

None reported